Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma

Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma

Abstract Although CD19-specific chimeric antigen receptor (CAR) T cells are curative for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), disease relapse with tumor antigen-positive remains a challenge. Cytokine/chemokine-expressing CAR-T cells could overcome a suppressive mili...

Full description

Bibliographic Details
Main Authors: Wen Lei, Ai Zhao, Hui Liu, Chunmei Yang, Cheng Wei, Shanshan Guo, Zhilu Chen, Qunyi Guo, Linjie Li, Mingzhe Zhao, Gongqiang Wu, Guifang Ouyang, Ming Liu, Jinyi Zhang, Jimin Gao, Wenbin Qian
Format: Article
Language:English
Published: Nature Publishing Group 2024-01-01
Series:Cell Discovery
Online Access:https://doi.org/10.1038/s41421-023-00625-0

Internet

https://doi.org/10.1038/s41421-023-00625-0

Similar Items